Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

Thrombocytopenic Purpura Clinical Trial

Official title:
An Open-label, Unit Dose-finding Study Evaluating the Safety and Efficacy of Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

Status Completed

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability of AMG 531 (romiplostim), a novel thrombopoiesis-stimulating peptibody, and its effect on platelet counts in adults with immune thrombocytopenic purpura.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Purpura
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic
Thrombocytopenic Purpura

Clinical Trial Details

NCT number	NCT00117143
Study type	Interventional
Source	Amgen
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	December 2, 2002
Completion date	July 19, 2004

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03244410` - Lymphocyte Counts in Immune Thrombocytopenic Purpura	N/A
Completed	`NCT00454857` - Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)	N/A
Completed	`NCT01444417` - Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients	Phase 3
Completed	`NCT00508820` - An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP	Phase 3
Completed	`NCT00415532` - Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura	Phase 3